Authors’ Reply to Rana et al. “Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials”

Usha Kant Misra1, Jayantee Kalita1, Mritunjai Kumar2, Methil Pradeep3
1Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
2Department of Neurology, All India Institute of Medical Sciences, Raipur, India
3K.G. Hospital and Post Graduate Institute, Coimbatore, India

Tóm tắt

Từ khóa


Tài liệu tham khảo

Rana PB, Jacob NT, Toms T, Bhure S. Comment on: “Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials”. Am J Cardiovasc Drugs 2019. https://doi.org/10.1007/s40256-019-00334-8 .

Ramakrishnan TC, Kumaravelu S, Narayan SK, Buddha SS, Murali C, Majeed PH, et al. Efficacy and safety of intravenous tenecteplase bolus in acute ischemic stroke: results of two open-label. Multicenter Trials. Am J Cardiovasc Drugs. 2018;18:387–95.

Thomas GR, Thibodeaux H, Errett CJ, Badillo JM, Keyt BA, Refino CJ, et al. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke. 1994;25:2072–8.

Lapchak PA, Araujo DM, Zivin JA. Comparison of tenecteplase with alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol. 2004;185:154–9.

Haley EC, Lyden PD, Johnston KC, Hemmen TM. TNK in Stroke Investigators and others. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke. 2005;36:607–12.

Haley EC, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, for the tenecteplase in stroke Investigators, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke results of a prematurely terminated randomized clinical trial. Stroke. 2010;41:707–11.

Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366:1099–107.

Huang X, Cheripelli BK, Lloyd SM, Kalladka D, Moreton FC, Siddiqui A, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol. 2015;14:368–76.

Bivard A, Huang X, Levi CR, Spratt N, Campbell BC, Cheripelli BK, et al. Tenecteplase in ischemic stroke offers improved recanalization Analysis of 2 trials. Neurology. 2017;89:62–7.

Campbell BC, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med. 2018;378:1573–82.

Baird AE. Paving the way for improved treatment of acute stroke with tenecteplase. N Engl J Med. 2018;378:1635–6.

Logallo N, Novotny V, Assmus J, Kvistad CE, Alteheld L, Rønning OM, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017;16:781–8.